Cambridge Cognition (LON:COG) Earns “Buy” Rating from Panmure Gordon

Cambridge Cognition (LON:COG)‘s stock had its “buy” rating reissued by equities research analysts at Panmure Gordon in a research report issued to clients and investors on Monday,Digital Look reports. They presently have a GBX 56 price objective on the stock. Panmure Gordon’s price target would suggest a potential upside of 86.67% from the company’s previous close.

Cambridge Cognition Trading Up 11.1%

Shares of Cambridge Cognition stock traded up GBX 3 during trading hours on Monday, reaching GBX 30. The stock had a trading volume of 79,229 shares, compared to its average volume of 20,832. The firm has a market capitalization of £13.97 million, a price-to-earnings ratio of -7.89 and a beta of 0.72. Cambridge Cognition has a 1 year low of GBX 23.90 and a 1 year high of GBX 47. The company has a current ratio of 0.65, a quick ratio of 0.96 and a debt-to-equity ratio of 92.53. The firm has a 50 day simple moving average of GBX 29.97 and a two-hundred day simple moving average of GBX 31.62.

About Cambridge Cognition

Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency.